fatty diacid chain comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-01. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
=== Cyclic mechanical reinforcement === Most catch bonds were demonstrated using force-clamp force spectroscopy where upon initial ramping, a constant force is loaded on the bond to observe how long the bond lasts, i.e., measuring the bond lifetime at a constant force. Catch bonds are revealed when the mean bond lifetime (reciprocally related to the rate of bond dissociation) increases with the clamped force. Zhu and colleagues demonstrated that bond lifetime measured at the force-clamp phase could be substantially prolonged if the initial ramping included two forms of pre-conditioning: 1) loading the bond by ramping the force to a high level (peak force) before clamping the force at a low level for lifetime measurement, and 2) loading and unloading the bond repeatedly by multiple force cycles before clamping the force at a peak value for lifetime measurement. This new bond type, termed cyclic mechanical reinforcement (CMR), is distinct from catch bond, but it nevertheless resembles catch bond in that the bond lifetime increases with the peak force and with the number of cycles used to pre-condition the bond. CMR has been observed for interactions between integrin alpha 5 beta 1 and fibronectin and between G-actin and G-actin or F-actin.
=== Chemistry === The aforementioned chemical shift came as a disappointment to physicists who had hoped that the resonance frequency of each nuclear species would be constant in a given magnetic field. But about 1951, chemist S. S. Dharmatti pioneered a way to determine the structure of many compounds by studying the peaks of nuclear magnetic resonance spectra. It can be a very selective technique, distinguishing among many atoms within a molecule or collection of molecules of very similar type but which differ only in terms of their local chemical environment. NMR spectroscopy is used to unambiguously identify known and novel compounds, and as such, is usually required by scientific journals for identity confirmation of synthesized new compounds. See the articles on carbon-13 NMR and proton NMR for detailed discussions. A chemist can determine the identity of a compound by comparing the observed nuclear precession frequencies to known or predicted frequencies. Further structural data can be elucidated by observing spin–spin coupling, a process by which the precession frequency of a nucleus can be influenced by the spin orientation of a chemically bonded nucleus. Spin–spin coupling is easily observed in NMR of hydrogen-1 (1H NMR) since its natural abundance is nearly 100%. Because the nuclear magnetic resonance timescale is rather slow, compared to other spectroscopic methods, changing the temperature of a T2* experiment can also give information about fast reactions, such as the Cope rearrangement or about structural dynamics, such as ring-flipping in cyclohexane.
== Diagnosis == The diagnosis of MADD needs to be considered in patients who have exercise induced myalgia, cramps and sometimes weakness. A mildly elevated creatine kinase may also occur. Exclusion of other muscular diseases such as McArdle's Disease and carnitine cycle abnormalities should occur. MADD may be identified if there is a lack of ammonia rise after forearm exercise testing. The diagnosis may then be confirmed with genetic testing.
In 1960, the SAC Airborne Command Post or "Looking Glass" was initiated, with the conversion of 5 (6 but 1 was reverted ) KC-135A tankers to Airborne Command Posts. In July 1960, operational testing began under the code name Looking Glass, with a SAC general officer always aboard each flight, and operated by the 34th Air Refueling Squadron at Offutt AFB. In August 1966, the mission transferred to the 38th Strategic Reconnaissance Squadron, to the 2nd Airborne Command and Control Squadron in April 1970, to the 7th Airborne Command and Control Squadron in July 1994, and to the USSTRATCOM's Strategic Communications Wing One in October 1998. In February 1961, the Strategic Air Command put Looking Glass mission on continuous airborne alert. Aircraft from the 34th Air Refueling Squadron were based at its headquarters at Offutt AFB, backed up by aircraft flying with the Second Air Force / 913th Air Refueling Squadron at Barksdale AFB, Louisiana, the Eighth Air Force / 99th Air Refueling Squadron at Westover AFB, Massachusetts, and the Fifteenth Air Force / 22d Air Refueling Squadron, March AFB, California. EC-135 Looking Glass aircraft were airborne 24 hours a day for over 29 years, until July 24, 1990, when "The Glass" ceased continuous airborne alert, but remained on ground or airborne alert 24 hours a day. The Looking Glass mission mirrors ground-based command, control, and communications (C3 or C³) located at the USSTRATCOM Global Operations Center (GOC) at Offutt AFB.
Sources: en.wikipedia.org
== Dosimetry == Therapeutic PRRT treatments typically involve several gigabecquerels (GBq) of activity. Several radiopharmaceuticals allow simultaneous imaging and therapy, enabling precise dosimetric estimates to be made. For example, the bremsstrahlung emission from 90Y and gamma emissions from 177Lu can be detected by a gamma camera. In other cases, imaging can be performed by labelling a suitable radionuclide to the same peptide as used for therapy. Radionuclides that can be used for imaging include gallium-68, technetium-99m and fluorine-18. Currently used peptides can result in high kidney doses, as the radiopharmaceutical is retained for relatively long periods. Renal protection is therefore used in some cases, taking the form of alternative substances that reduce the uptake of the kidneys.
Portugal has been a semi-presidential representative democratic republic since the ratification of the Constitution of 1976. The Constitution divides the core structures of the Portuguese political system among four sovereignty organs: the president, the government, the Assembly of the Republic, and the courts. There is universal suffrage for adults over 18 years of age, with a secret ballot for all elected offices. Portugal operates a competitive multi-party system at the national, regional, and local levels. There have been trends towards autocratisation. The head of state of Portugal is the president who is elected to a five-year term by direct, universal adult suffrage. The president is usually regarded as politically independent and carries moderating powers aimed at ensuring the regular functioning of institutions and constitutional guarantees; in addition, it includes supreme command of the armed forces, and shapes political opinions and agendas. The current president of Portugal is António José Seguro; he took office after winning the runoff vote of the 2026 Portuguese presidential election.
Dahlgren (1985) suggested there were in fact forty – not one – families distributed over three orders (predominantly Liliales and Asparagales). In the context of a general review of the classification of angiosperms, the Liliaceae were subjected to more intense scrutiny. Considerable progress in plant phylogeny and phylogenetic theory enabled a phylogenetic tree to be constructed for all of the flowering plants, as elaborated by the Angiosperm Phylogeny Group (1998).
Sources: en.wikipedia.org
=== Cell migration === Histatins enhance migration in oral keratinocytes, fibroblasts, and endothelial cells. By increasing the number of fibroblast cells, histatin improves collagen deposition as well. Histatin 1 activates Rac1 GTPase through the RIN2/Rab5 signaling axis, facilitating cell adhesion and vascular morphogenesis.
Brown and white granulated sugar are 97% to nearly 100% carbohydrates, respectively, with less than 2% water, and no dietary fibre, protein or fat (table). Because brown sugar contains 5–10% molasses reintroduced during processing, its value to some consumers is a richer flavour than white sugar.
== Bibliography == Chapple, Christopher Key (1993), Nonviolence to Animals, Earth, and Self in Asian Traditions, State University of New York Press Crane, Eva, ed. (1975). Honey: A Comprehensive Survey. London: Heinemann. ISBN 9780434902705. Crane, Eva (1980). A Book of Honey. New York: Charles Scribner's Sons. ISBN 9780684166513. OCLC 7172738. Jaini, Padmanabh S. (1998) [1979], The Jain Path of Purification, Delhi: Motilal Banarsidass, ISBN 978-81-208-1578-0 Krell, R. (1996). Value-added products from beekeeping. Food and Agriculture Organization of the United Nations. p. 5. ISBN 978-92-5-103819-2. Retrieved 5 January 2016. Root, A. I.; Root, E. R. (2005) [1879]. The ABC and XYZ of Bee Culture. Kessinger Publishing. ISBN 978-1-4179-2427-1. Retrieved 5 January 2016.
=== Genome === Chinese scientists published a draft genome of Ginkgo biloba in 2016. The tree has a large genome of 10.6 billion DNA nucleobase "letters" (the human genome has three billion) and about 41,840 predicted genes which enable a considerable number of antibacterial and chemical defense mechanisms. 76.58% of the assembled sequence turned out to be repetitive sequences. In 2020, a study in China of ginkgo trees up to 667 years old showed little effects of aging, finding that the trees continued to grow with age and displayed no genetic evidence of senescence, and continued to make phytochemicals indefinitely.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.